NCT05269940 is a Phase 1, PHASE2 clinical trial of ZX-101A in Non Hodgkin Lymphoma, sponsored by Nanjing Zenshine Pharmaceuticals.

Who is sponsoring NCT05269940?

NCT05269940 is sponsored by Nanjing Zenshine Pharmaceuticals.

What drugs are being tested in NCT05269940?

Interventions in NCT05269940: ZX-101A.

What condition does NCT05269940 study?

NCT05269940 studies Non Hodgkin Lymphoma, Peripheral T Cell Lymphoma, CLL/SLL.

Is NCT05269940 still recruiting?

NCT05269940 is currently completed. Last updated 13 November 2024.

Last reviewed 2024-11-13 · How we verify

NCT05269940

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies

Completed Phase 1, PHASE2 Last updated 13 November 2024

What this trial tests

Phase 1, PHASE2 trial testing ZX-101A in Non Hodgkin Lymphoma in 40 participants. Completed in 5 July 2024.

Timeline

17 February 2022

Primary endpoint
24 January 2023

5 July 2024

Quick facts

Lead sponsor	Nanjing Zenshine Pharmaceuticals
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	17 February 2022
Primary completion	24 January 2023
Estimated completion	5 July 2024
Sites	3 locations across China

Drugs / interventions tested

ZX-101A — full drug profile →

Conditions studied

Non Hodgkin Lymphoma — all drugs for Non Hodgkin Lymphoma →
Peripheral T Cell Lymphoma — all drugs for Peripheral T Cell Lymphoma →
CLL/SLL — all drugs for CLL/SLL →

Sponsor

Nanjing Zenshine Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Non Hodgkin Lymphoma or Peripheral T Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

ZX-101A-202 is a Phase I, open-label, multicenter study, a single-agent dose-escalation and dose-expansion study of ZX-101A. It is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacokinetics, efficacy and antitumor activity of ZX-101A in patients with relapsed/refractory hematological malignancies.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical landscape of macrophage-reprogramming cancer immunotherapies.
Rannikko JH, Hollmén M. · · 2024 · cited 70× · PMID 38831013 · DOI 10.1038/s41416-024-02715-6
Therapeutic challenges in peripheral T-cell lymphoma.
Luan Y, Li X, Luan Y, Luo J, et al · · 2024 · cited 34× · PMID 38178117 · DOI 10.1186/s12943-023-01904-w

Verify or expand the search:

Other trials of ZX-101A

Trials testing the same drug.

NCT05258266 — A Study to Evaluate the Activity, Safety and Tolerability of ZX-101A in Advanced Solid Tumors · Phase 1, PHASE2 · unknown
NCT04504708 — Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematolog · Phase 1, PHASE2 · terminated

Other recruiting trials for Non Hodgkin Lymphoma

Currently open trials in the same condition.

NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07016165 — Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Maligna · Phase 4 · recruiting
NCT06622226 — A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma · Phase 1 · active not recruiting
NCT06522932 — PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy · Phase 1 · recruiting
NCT06116110 — Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU · recruiting

Other Nanjing Zenshine Pharmaceuticals trials

Trials by the same sponsor.

NCT07310134 — Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ZX-8177 in Patients With Adva · Phase 1 · recruiting
NCT07095257 — Study to Assess the Safety and Efficacy of ZX-7101A for Oral Suspension in Chinese Pediatric Participants 2 to 11 Years · Phase 3 · completed
NCT06841926 — Study to Evaluate the Pharmacokinetics and Relative Bioavailability of Metabolites in Healthy Chinese Adult Males · Phase 1 · completed
NCT06669351 — Study to Assess the Safety and Efficacy of ZX-7101A in Children Aged 5-11 Years With Influenza · Phase 3 · terminated
NCT06099873 — Study to Assess the Safety and Efficacy of ZX-7101A in Adolescents With Influenza · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05269940 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nanjing Zenshine Pharmaceuticals
Last refreshed: 13 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05269940.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing